The "cellular optimization" fat-loss molecule — mechanistically elegant, entirely animal-tested. Three points define this entry: (1) it is not a peptide — a small-molecule enzyme inhibitor, expanding the register's non-peptide tier; (2) it works by a genuinely different route from GLP-1 drugs — dire
5-Amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) studied for fat loss through a mechanism quite different from GLP-1 drugs: instead of curbing appetite, it acts inside fat cells. NNMT normally consumes SAM (the cell's methyl donor) and pulls nicotinamide out of the NAD⁺ salvage pathway; inhibiting it raises SAM and NAD⁺, boosting sirtuin (SIRT1/3) activity, fat oxidation, thermogenesis and polyamine flux — and NNMT is expressed highest in adipose tissue, offering the theoretical appeal of a fat-targeted intervention. The preclinical evidence is genuinely interesting: in diet-induced obese mice, 5-Amino-1MQ reduced body weight, fat mass, adipocyte size (~30–40%) and total cholesterol (~30%) without changing food intake or lean mass, and a separate line showed muscle-stem-cell reactivation in aged mice. The decisive caveat: every efficacy result is in rodents or cell culture. There are no completed human trials, no published human pharmacokinetics, and no approval anywhere. Elegant mechanism, essentially no human proof.
not approved anywhere; investigational research chemical. Not a cosmetic; not on the FDA 503A bulk-compounding list (no legitimate compounding/clinical access route). Sold as a "research use only" small molecule.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (watch for first-in-human PK/efficacy trials — that would be the first thing to move any grade off F).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.